Astrazeneca annual gross profit
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Astrazeneca Gross Profit Growth & History (AZN)
Astrazeneca's gross profit was $48.11B for fiscal 2025.
View full Astrazeneca company overviewAstrazeneca annual gross profit history
| Fiscal year | Period ended | Gross profit | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $48.11B | $4.24B | +9.67% |
| 2024 | 2024-12-31 | $43.87B | $6.32B | +16.84% |
| 2023 | 2023-12-31 | $37.54B | $5.58B | +17.47% |
| 2022 | 2022-12-31 | $31.96B | $6.98B | +27.94% |
| 2021 | 2021-12-31 | $24.98B | $3.66B | +17.18% |
| 2020 | 2020-12-31 | $21.32B | $1.85B | +9.53% |
| 2019 | 2019-12-31 | $19.46B | $2.31B | +13.46% |
| 2018 | 2018-12-31 | $17.15B | −$993.0M | −5.47% |
| 2017 | 2017-12-31 | $18.15B | −$729.0M | −3.86% |
| 2016 | 2016-12-31 | $18.88B | −$1.19B | −5.91% |
| 2015 | 2015-12-31 | $20.06B | — | — |
Astrazeneca quarterly gross profit
Q2.17
Q2.18
Q2.19
Q2.20
Q2.21
Q2.22
Q2.23
Q2.24
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Gross profit | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $12.86B | $877.0M | +7.32% |
| Q1 2026 | 2026-03-31 | $12.61B | — | — |
| Q4 2025 | 2025-12-31 | $12.38B | — | — |
| Q3 2025 | 2025-09-30 | $12.39B | — | — |
| Q2 2025 | 2025-06-30 | $11.98B | $1.23B | +11.43% |
| Q2 2024 | 2024-06-30 | $10.76B | $1.30B | +13.74% |
| Q2 2023 | 2023-06-30 | $9.46B | $1.68B | +21.65% |
| Q2 2022 | 2022-06-30 | $7.77B | $1.74B | +28.93% |
| Q2 2021 | 2021-06-30 | $6.03B | $738.0M | +13.95% |
| Q2 2020 | 2020-06-30 | $5.29B | $531.0M | +11.16% |
| Q2 2019 | 2019-06-30 | $4.76B | $617.0M | +14.89% |
| Q2 2018 | 2018-06-30 | $4.14B | $42.0M | +1.02% |
| Q2 2017 | 2017-06-30 | $4.10B | — | — |
Astrazeneca gross profit trends
Over the last five fiscal years, Astrazeneca's gross profit increased from $21.32B to $48.11B, a change of $26.79B. The latest reported quarter, Q2 2026, shows $12.86B.
About the metric
What gross profit means
Gross profit is the amount of revenue remaining after the direct costs of producing and delivering a company’s goods or services. It helps show the dollars available to cover operating expenses before operating income, interest, and taxes.
Calculation and source
SEC-reported and calculated gross profit
TickerStat uses gross profit reported in company SEC filings when available. Otherwise, it calculates gross profit as SEC-reported revenue minus aligned cost of revenue for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Astrazeneca source filings ↗Community posts
AstraZeneca receives US accelerated approval for Etcamah in a defined breast-cancer setting
AstraZeneca announced US accelerated approval of Etcamah on 7 September 2026. Approved setting Camizestrant, combined with a CDK4/6 inhibitor, is approved for adults with HR-positive, HER2-negative locally advanced or metastatic breast canc ...